Correspondence on 'Outcomes of stage IV melanoma in the era of immunotherapy: a National Cancer Database (NCDB) analysis from 2014 to 2016' by Sussman et al.
作者信息
Grant Christopher, Hagopian Garo, Tran Thuy B, Nagaraj Gayathri, Moyers Justin T
机构信息
Department of Medicine, University of California Irvine, Irvine, California, USA.
Division of Surgical Oncology, Department of Surgery, University of California Irvine, Irvine, California, USA.
出版信息
J Immunother Cancer. 2022 Dec;10(12). doi: 10.1136/jitc-2022-006187.
Abstract
摘要
相似文献
1
Correspondence on 'Outcomes of stage IV melanoma in the era of immunotherapy: a National Cancer Database (NCDB) analysis from 2014 to 2016' by Sussman et al.苏斯曼等人关于“免疫治疗时代IV期黑色素瘤的结局：2014年至2016年国家癌症数据库（NCDB）分析”的通信
J Immunother Cancer. 2022 Dec;10(12). doi: 10.1136/jitc-2022-006187.
2
Use of immunotherapy and surgery for stage IV melanoma.免疫疗法和手术在 IV 期黑色素瘤中的应用。
Cancer. 2020 Jun 1;126(11):2614-2624. doi: 10.1002/cncr.32817. Epub 2020 Mar 10.
3
Outcomes of stage IV melanoma in the era of immunotherapy: a National Cancer Database (NCDB) analysis from 2014 to 2016.免疫治疗时代 IV 期黑色素瘤的结局：2014 年至 2016 年国家癌症数据库（NCDB）分析。
J Immunother Cancer. 2022 Aug;10(8). doi: 10.1136/jitc-2022-004994.
4
Association of Insurance Status With Presentation, Treatment, and Survival in Melanoma in the Era of Immune Checkpoint Inhibitors.保险状况与免疫检查点抑制剂时代黑色素瘤的表现、治疗和生存的关联。
J Immunother. 2020 Jan;43(1):8-15. doi: 10.1097/CJI.0000000000000294.
5
Treatment of melanoma of unknown primary in the era of immunotherapy and targeted therapy: A Dutch population-based study.免疫治疗和靶向治疗时代不明原发灶黑色素瘤的治疗：一项荷兰基于人群的研究。
Int J Cancer. 2020 Jan 1;146(1):26-34. doi: 10.1002/ijc.32229. Epub 2019 Mar 20.
6
Utilization and impact of immunotherapy in stage IV melanoma using the National Cancer Database.利用国家癌症数据库评估免疫疗法在 IV 期黑色素瘤中的应用和影响。
Melanoma Res. 2020 Aug;30(4):376-385. doi: 10.1097/CMR.0000000000000672.
7
Use of extracranial radiation therapy in metastatic melanoma patients receiving immunotherapy.转移性黑色素瘤患者接受免疫治疗时采用颅外放射治疗。
Radiother Oncol. 2018 May;127(2):310-317. doi: 10.1016/j.radonc.2018.02.022. Epub 2018 Mar 11.
8
Time from stereotactic radiosurgery to immunotherapy in patients with melanoma brain metastases and impact on outcome.脑转移黑色素瘤患者接受立体定向放射外科手术与免疫治疗的时间间隔及其对预后的影响。
J Neurooncol. 2021 Mar;152(1):79-87. doi: 10.1007/s11060-020-03663-w. Epub 2021 Jan 11.
9
Immunotherapy for advanced melanoma: future directions.晚期黑色素瘤的免疫疗法：未来方向
Immunotherapy. 2016 Feb;8(2):199-209. doi: 10.2217/imt.15.111. Epub 2016 Jan 25.
本文引用的文献
1
Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti-PD-1 Era.在抗 PD-1 时代，一线免疫检查点抑制剂的使用与转移性黑色素瘤患者的总生存相关。
JAMA Netw Open. 2022 Aug 1;5(8):e2225459. doi: 10.1001/jamanetworkopen.2022.25459.
2
Outcomes of stage IV melanoma in the era of immunotherapy: a National Cancer Database (NCDB) analysis from 2014 to 2016.免疫治疗时代 IV 期黑色素瘤的结局：2014 年至 2016 年国家癌症数据库（NCDB）分析。
J Immunother Cancer. 2022 Aug;10(8). doi: 10.1136/jitc-2022-004994.
3
Association of Sociodemographic Factors With Immunotherapy Receipt for Metastatic Melanoma in the US.社会人口因素与美国转移性黑色素瘤免疫治疗接受的关联。
JAMA Netw Open. 2020 Sep 1;3(9):e2015656. doi: 10.1001/jamanetworkopen.2020.15656.
4
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.帕博利珠单抗对比伊匹单抗用于晚期黑色素瘤（KEYNOTE-006）：一项开放标签、多中心、随机、对照、III 期研究的 5 年随访后结果。
Lancet Oncol. 2019 Sep;20(9):1239-1251. doi: 10.1016/S1470-2045(19)30388-2. Epub 2019 Jul 22.
5
Association of Delays in Surgery for Melanoma With Insurance Type.黑色素瘤手术延迟与保险类型的关联。
JAMA Dermatol. 2017 Nov 1;153(11):1106-1113. doi: 10.1001/jamadermatol.2017.3338.
Zotero 插件